I-MAB (IMAB) Gets a Buy Rating from Needham
markets.co - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from markets.co Daily Mail and Mail on Sunday newspapers.
I-MAB (IMAB) Q2 2021 Earnings Call Transcript
fool.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fool.com Daily Mail and Mail on Sunday newspapers.
I-MAB (IMAB) Gets a Buy Rating from Needham
In a report released today, Chad Messer from Needham assigned a Buy rating to I-MAB (IMAB – Research Report), with a price target of $75.00. The company’s shares closed last Monday at $64.01, close to its 52-week high of $65.94.
According to TipRanks.com, Messer is a 4-star analyst with an average return of 8.0% and a 46.2% success rate. Messer covers the Healthcare sector, focusing on stocks such as Mereo Biopharma Group Plc, Phasebio Pharmaceuticals, and Aeglea Biotherapeutics.
Currently, the analyst consensus on I-MAB is a Strong Buy with an average price target of $75.20.
Based on I-MAB’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.54 billion and net profit of $1.04 billion. In comparison, last year the company earned revenue of $15 million and had a GAAP net loss of $246 million.